Ronnie Yeager
Research Fellow, Emerging Therapeutic Platforms (Development Sciences) Director Abbvie
Seminars
Wednesday 13th May 2026
Panel Discussion: Regulatory & Pharma Expectations in the Adoption of NAMs: IQ MPS Affiliate Perspective
3:00 pm
- How pharma teams are collaborating within IQ MPS Affiliate to progress simple and complex in vitro NAM platforms toward regulatory acceptance
- Review insights from recent FDA publication on submitted NAM case examples and reviewer feedback – what works and what can be improved (need for well-articulated context-of-use)
- Where AI-enabled validation initiatives like VICT3R can strengthen confidence by benchmarking prediction accuracy against real clinical outcomes
- Gain practical guidance for integrating in vitro and in silico NAMs into toxicology packages without over-claiming translatability
- What industry needs from consortia, regulators, and data-sharing frameworks to accelerate adoption of novel platforms covering diverse mechanisms of injury
Wednesday 13th May 2026
Case Study of Microphysiological System Models for ILD: Developing In Vitro Assays for Evaluating ADC Lung Safety
11:30 am
- Leveraging complex in vitro models to evaluate ADC-induced lung toxicity
- Building in vitro tools for high-throughput compound screening
- Pending relevance to pathogenesis of ILD, high-throughput imaging-based assays may potentially be incorporated into a holistic screening approach to differentiate ADCs and guide selection of safer compounds
